CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Roche bets $1B+ on DualityBio's ADC tech to tackle TOPO1 resistance

PartnershipPositive
AI Analysis

Summary

Roche's Genentech partnered with DualityBio to develop ADC drugs targeting TOPO1 resistance, with DualityBio receiving $45 million upfront and potential for over $1 billion in total deal value.

Importance:7/10
Sentiment:
0.70
antibody-drug conjugatesADCpartnershiplicensing
Related Companies

Read the original article

Published by Endpoints News on August 28, 2026 11:30 AM

Read Original